|
||
Brief Definitive Reports |



DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, California, 94304-1104
| Abstract |
|---|
|
|
|---|
Secondary lymphoid organs such as lymph nodes, spleen, Peyer's patches, and tonsils represent the major sites where immune responses to antigens occur. These lymphoid organs are divided into a T cell compartment (T cell zone or extrafollicular area) and a B cell compartment (B lymphoid follicle). While T cell zones contain interdigitating dendritic cells that play key roles in presenting antigen to naive T cells (1), B cell follicles contain follicular dendritic cells (FDC) that have the capacity to retain native antigen–antibody immune complexes for long periods of time (2, 3). During T cell–dependent humoral (antibody) immune responses, antigen-specific B cells undergo rapid clonal expansion within the FDC networks of B cell follicles, leading to the formation of germinal centers (GC) (4). During the course of clonal expansion, somatic hypermutation in immunoglobulin variable region genes (5, 6), and isotype switch in immunoglobulin constant region genes occur (7). After antigen-driven affinity selection (8), high affinity germinal center B cells will differentiate into either plasma cells or memory B cells (9–11). The functions of FDC in the GC reaction were proposed because of their selective localization and their ability to retain immune complexes. Both in vivo and in vitro experiments have suggested that FDC play important roles in GC B cell proliferation, survival, and differentiation (12–15). However, little is known at the molecular level of how FDCs contribute to GC development. Several monoclonal antibodies have been generated against FDCs (16, 17); however, the nature and function of the antigens recognized by these monoclonal antibodies are unknown. Here, we describe an antibody (mAb 7D6) that specifically recognizes human FDC. By expression cloning, using mAb 7D6, a cDNA clone encoding for the long isoform of CD21L (CD21L) that contains an additional exon (10a) was isolated. We show that FDC selectively express CD21L, while B cells selectively express the short CD21 (CD21S) lacking exon 10a. By screening mouse L cells transfected with the CD21L cDNA, we further demonstrate that the other two anti–human FDC mAbs, DRC-1 and KiM4, also recognize CD21.
Isolation of a Highly Purified Single FDC Suspension by FACS® Sorting of CD14+CD21+ Large Tonsillar Cells.
![]()
Materials and Methods
Top
Abstract
Materials and Methods
Results and Discussion
References
Isolation of FDC from Human Tonsils by Percoll Gradient.
Tonsils obtained from children undergoing tonsillectomy were cut into small pieces and digested for 12 min at 37°C with an enzyme cocktail in RPMI 1640 medium (GIBCO BRL, Gaithersburg, MD) containing collagenase IV (1 mg/ml; Sigma Chemical Co., St. Louis, MO) and deoxyribonuclease I (50 kU/ml; Sigma Chemical Co.). The released cells were collected and a new stock of enzyme solution was added to the remaining tissue fragments for another 12 min. The cells, collected after two successive rounds of enzymatic digestion, were pooled and centrifuged through Ficoll-Hypaque (Eurobio, Paris, France) for 20 min at 400 g to remove red and dead cells. After two washes, cells were layered on a 1.5% BSA (Pentex® Path-o-cyte 5; Miles Inc., Kankakee, IL) gradient and centrifuged at 10 g for 10 min at 4°C. The FDC-lymphocyte clusters were recovered from the pellet. This BSA gradient process was repeated two to three times. The resulting cell population contains 15–30% FDC that form tight clusters with lymphocytes (13).
Since human B cells, T cells, fibroblasts, endothelial cells, and epithelial cells express no or low levels of CD14, and human T cells, fibroblasts, endothelial cells, and epithelial cells express no or low levels of CD21, CD14highCD21high FDC were isolated by FACS® sorting of enriched FDC preparations by Percoll gradient. After cell sorting, the resulting population contained >98% pure single FDC (Fig. 3). These highly purified FDCs may have been damaged inasmuch as they displayed cytoplasm losses and were unable to support B cell growth in vitro. However, these cells were used for PCR assays.
|
Generating FDC-specific mAb 7D6.
BALB/c mice were immunized with 5 x 106 enriched human tonsillar FDC intraperitoneally three times at 3-wk intervals. The final boost was carried out 3 d before fusion. Using polyethylene glycol 1500 (Boehringer Mannheim GmbH, Mannheim, Germany), 50 x 106 splenic cells were fused with NS1 myeloma cells. Hybridomas were cultured in complete medium supplemented with 20% vol/vol FCS, hypoxanthine and azaserine, oxaloacetic acid, pyruvate, and insulin (OPI; Sigma Chemical Co.). Hybridomas were selected by immunohistological staining of the culture supernatants of the FDC networks on tonsillar tissue sections. Ascites was produced in BALB/c mice, and mAb 7D6 (IgG1) was purified by highpressure liquid chromatography with an anion-exchange column (DEAE 5PW; Waters Chromatography Div., Milford, MA).
Immunoenzymatic Staining.
Frozen sections from human tonsils, spleen, and thymus were washed in PBS for 5 min. The sections were incubated with mouse IgG1 mAb 7D6, anti-CD21, and anti-CD54, respectively, for 60 min. After washing for 5 min in PBS, the sections were incubated with sheep anti–mouse IgG1 for 30 min in PBS containing 10% human serum, and then with alkaline phosphatase coupled to mouse antibodies specific for alkaline phosphatase (APAAP complexes; Dako, Roskilde, Denmark). After a final washing, alkaline phosphatase was developed by Fast red substrate (Sigma Chemical Co.) which gives a red color. Cytospin preparations of FDC clusters were fixed in acetone for 10 min at 4°C. The slides were washed in PBS and incubated for 1 h with the anti-FDC mAb 7D6. After washing, the cytospin slides were incubated for 30 min with anti–mouse IgG1. The binding of antibody was revealed using APAAP method and developed by Fast red substrate.
cDNA Library Construction and Screening.
Poly(A)+ RNA was purified from a B lymphoblastic cell line IM9 established from a bone marrow sample of a myeloma patient. This cell line stained weakly (variable;
28% positive cells) with mAb 7D6. cDNA library construction was as described (18) using the Superscript Reverse Transcriptase cDNA Synthesis Kit (GIBCO BRL). Doublestranded cDNA was size-fractionated using a Chromaspin-1000 column (Clontech, Palo Alto, CA) and ligated into the BstxI/ NotI-digested pJFE14 expression vector (19).
A cDNA clone encoding the 7D6 antigen was isolated by a method similar to that described (18) except that cell sorting (FACS®), rather than panning, was used to enrich COS7 cells transiently expressing the 7D6 antigen (20). After a 1 h incubation with 50 µg/ml isotype IgG1 antibody to block binding to Fc
R, COS7 cells were stained with 10 µg/ml biotinylated mAb 7D6. Cells which bound mAb 7D6 were detected with streptavidin–phycoerythrin (Becton Dickinson, Milpitas, CA). Plasmid DNA recovered from sorted cells was transformed into Escherichia coli DH10B for expansion and then reintroduced into COS7 cells. A cDNA clone (p7D6) with a 4 kb insert was identified which encoded the antigen recognized by mAb 7D6. The sequence of the cDNA insert was determined in part manually as described (18), and in part on an automated sequencer (Applied Biosystems, Foster City, CA) using Taq Dye Deoxy Terminator cycle sequencing.
Expression of the 7D6 Antigen.
The 7D6 cDNA clone was expressed transiently in COS7 cells (18). Mouse Ltk– cells (L cells) stably expressing the 7D6 antigen were generated by cotransfection with a neomycin-resistance plasmid by the calcium phosphate method (GIBCO BRL). Cells which survived in 1 mg/ml G418 were selected for 7D6 expression by FACS® and also were positive for CD21 (CALTAG Labs., South San Francisco, CA).
PCR Assay to Detect the Expression of Short and Long CD21 Isoforms.
mRNA was extracted from 104 FDC purified by FACS® sorting according to their high expression of CD21 and CD14 antigens. cDNA was obtained by reverse transcription (Superscript Reverse Transcriptase Kit; GIBCO BRL). PCR assay was performed using a 5' primer UHCR2-1704 (GGAGAGAGCACCATCCGTTG), a 3' primer ULCR2-2363 (GGGCAGCGAGTCACAGGAGGAG) (see Fig. 2), and a taq polymerase (Perkin-Elmer Corp., Norwalk, CT) in a thermal cycler. The first cycle of denaturation was at 94°C for 3 min, and then 35 cycles including 1 min of denaturation at 94°C, 2 min for primer annealing at 60°C, and 3 min of extension at 72°C. Complete extension was achieved for 10 min at 72°C. PCR products were loaded on a 1% low melting point gel for purification (WIZARD PCR DNA Purification System; Promega Biotec, Madison, WI). These products were ligated and cloned in the PCRtmII vector with TA cloning kit (Invitrogen, San Diego, CA). Plasmids were extracted from individual bacterial colonies and both strands were sequenced on an automated DNA sequencer (Applied Biosystems) using PCR II vector primers (21 M13, and M13RP).
|
| Results and Discussion |
|---|
|
|
|---|
|
A AT (Asn)] and position 2075 [CGT (Arg)
CAT (His)] (The sequence of the 7D6-reactive isoform of CD21 is available upon request). Consistent with this finding, all the anti-CR2/CD21 mAbs available from the Fifth International Leukocyte Typing Workshop that had been shown to stain both B cells and FDCs, stained p7D6 cDNA transfected Cos7 cells or L cells (not shown). However, mAb 7D6 is specific for FDC, and does not recognize CD21 expressed on other cells. Two CD21 isoforms have been described. A "long" form (CD21L) has an extracellular domain with 16 short consensus repeats (SCR) (Fig. 2), and is encoded by p7D6 and the clone described earlier (23). A short CD21 isoform was reported with an extracellular domain containing only 15 SCRs, the missing SCR (SCR10a) of 59 amino acids being encoded by 177 bp (Fig. 2) (23). Whether the mAb 7D6 epitope is encoded by SCR10a, or is a conformational determinant induced elsewhere in the molecule by the presence of SCR10a, is not known.
Human B Cells Selectively Express the CD21S; FDC Selectively Express CD21L.
The pattern of mAb 7D6 staining suggests that FDC specifically express CD21L, while B cells specifically express CD21S. To directly test this hypothesis, a PCR assay using a 5' primer starting from basepair 1704 and a 3' primer starting from basepair 2363 of the short CR2/CD21 sequence, was carried out on RNA from 104 highly purified FDC (Fig. 3) in parallel with follicular mantle B cells (FM) and GC B cells isolated by FACS® sorting. Fig. 4 shows that a single large PCR product was generated from FDC, and a single smaller PCR product was generated from both FM and from GC B cells of the same donor. Further, sequencing analysis of these two PCR products shows that the FDC-derived large PCR product is 836 bp containing the 177-bp insertion that encodes the SCR10a. The B cell–derived PCR product is 659 bp, which does not contain the 177-bp insert (Fig. 5).
|
|
In conclusion, the present study demonstrates that FDC express the SCR10a-containing CD21L, and this long form of CD21 appears to be a specific cell surface marker for FDC. In contrast, B cells express the short form of CD21. The low frequency of isolation of CD21L cDNAs from a tonsillar cDNA library reported earlier was probably due to the fact that FDC are considerably less abundant in tonsil than B cells (23). Thus, FDC and B cells exhibit a cell type–specific splicing mechanism for CD21 expression.
CR2/CD21 has been shown to play key roles in B cell activation and humoral immune responses. Monoclonal anti-CD21 and a recombinant CD21-Ig fusion protein suppressed IgG responses to T cell–dependent antigens in mice (24, 25). CD21-deficient mice exhibit deficiencies in a B cell (B-1a) compartment, and in their ability to generate a T-dependent antibody response and GC reaction (26). Remarkably, antigen (hen egg lysozyme; HEL) attached to C3d (HEL-C3d) was 1,000–10,000-fold more immunogenic than HEL alone when these antigens were administered to mice (27). Several possible mechanisms have been proposed for the biological functions of CR2/ CD21: (a) long-term retaining and presenting native antigens in the form of immune complexes on FDC, (b) binding the B cell activation antigen CD23/Fc
RII (28), and (c) serving as a co-receptor for B cell activation within the TAPA-1/CD19/CD21 complex (29).
The differential expression of CD21L and CD21S, respectively, on FDCs and B cells, may suggest their different functions. For example, understanding the functional significance of the additional SCR10a exon may provide a clue for explaining the mechanisms by which FDCs retain native antigen and costimulate GC B cells. The availability of anti-CD21L antibodies specific for FDCs will facilitate their purification after studies of their developmental pathway and their functional characterization.
| Acknowledgments |
|---|
Submitted: 19 August 1996
Revised: 16 October 1996
| References |
|---|
|
|
|---|
1 Steinman RM & Nussenzweig MC. Dendritic cells: features and functions, Immunol Rev, 1980, 53, 127–147.[Medline]
2 Nossal GJV, Abbot A, Mitchell J & Lummus Z. Antigens in immunity. XV. Ultrastructural features of antigen capture in primary and secondary lymphoid follicles, J Exp Med, 1968, 127, 277–290.[Abstract]
3 Tew JG, Kosco MH, Burton GF & Szakal AK. Follicular dendritic cells as accessory cells, Immunol Rev, 1990, 117, 185–211.[Medline]
4 Liu YJ, Johnson GD, Gordon J & MacLennan ICM. Germinal centers in T-cell–dependent antibody responses, Immunol Today, 1992, 13, 17–21.[Medline]
5 Berek C, Berger A & Apel M. Maturation of the immune response in germinal centers, Cell, 1991, 67, 1121–1129.[Medline]
6 Jacob J, Kelsoe G, Rajewsky K & Weiss U. Intraclonal generation of antibody mutants in germinal centres, Nature (Lond), 1991, 354, 389–392.[Medline]
7 Liu YJ, Malisan F, de Bouteiller O, Guret C, Lebecque S, Banchereau J, Mills FC, Max EE & Martinez-Valdez H. Within germinal centers isotype switching of immunoglobulin genes occurs after onset of somatic mutation, Immunity, 1996, 4, 241–250.[Medline]
8 Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J & MacLennan ICM. Mechanisms of antigendriven selection in germinal centers, Nature (Lond), 1989, 342, 929–931.[Medline]
9 Kosco VMH, Burton GF, Kapasi ZF, Szakal AK & Tew JG. Antibody-forming cell induction during an early phase of germinal centre development and its delay with ageing, Immunology, 1989, 68, 312–318.[Medline]
10 Coico RF, Siskind GW & Thorbecke GJ. Role of IgD and T cells in the regulation of the humoral immune response, Immunol Rev, 1988, 105, 45–67.[Medline]
11 Arpin C, Dechanet J, van Kooten C, Merville P, Grouard G, Brière F, Banchereau J & Liu Y-J. Generation of memory B cells and plasma cells in vitro, Science (Wash DC), 1995, 268, 720–722.
12 Burton GF, Conrad DH, Szakal AK & Tew JG. Follicular dendritic cells and B-cell costimulation, J Immunol, 1993, 150, 31–38.[Abstract]
13 Grouard G, de Bouteiller O, Banchereau J & Liu Y-J. Human follicular dendritic cells enhance cytokine dependent growth and differentiation of CD40 activated B cells, J Immunol, 1995, 155, 3345–3352.[Abstract]
14 Lindhout E, Mevissen ML, Kwekkeboom J, Tager JM & de-Groot C. Direct evidence that human follicular dendritic cells (FDC) rescue germinal center cells from death by apoptosis, Clin Exp Immunol, 1993, 91, 330–336.[Medline]
15 Kosco-Vilbois VMH, Gray D, Scheidegger D & Julius M. Follicular dendritic cells help resting B cells to become effective antigen-presenting cells: induction of B7/ BB1 and upregulation of major histocompatibility complex class II molecules, J Exp Med, 1993, 178, 2055–2066.
16 Naiem M, Gerdes J, Abdulaziz Z, Stein H & Mason DY. Production of a monoclonal antibody reactive with human dendritic reticulum cells and its use in the immunohistological analysis of lymphoid tissue, J Clin Pathol (Lond), 1983, 36, 167–175.
17 Parwaresch MR, Radzun HJ, Feller AC, Peters KP & Hansmann ML. Peroxidase-positive mononuclear leukocytes as possible precursors of human dendritic reticulum cells, J Immunol, 1983, 131, 2719–2725.[Abstract]
18 Ho AS-Y, Liu Y, Khan TA, Hsu D-H, Bazan JF & Moore WK. A receptor for interleukin-10 is related to interferon receptors, Proc Natl Acad Sci USA, 1993, 90, 11267–11271.
19 Elliott JF, Albrecht GR, Gilladoga A, Handunetti S, Neequaye J, Lallinger G, Minjas JN & Howard RJ. Genes for plasmodium falciparum surface antigens cloned by expression in COS cells, Proc Natl Acad Sci USA, 1990, 87, 6363–6367.
20 MacNeil I, Kennedy J, Godfrey DI, Jenkins NA, Masciantonio M, Mineo C, Gilbert DJ, Copeland NG, Boyd RI & Zlotnik A. Isolation of a cDNA encoding thymic shared antigen-1. A new member of the Ly6 family with a possible role in T cell development, J Immunol, 1993, 151, 6913–6923.[Abstract]
21 Moore MD, Cooper NR, Tack BF & Nemerow GR. Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes, Proc Natl Acad Sci USA, 1987, 84, 9194–9198.
22 Fujisaku A, Harley JB, Frank MB, Gruner BA, Frazier B & Holers VM. Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor, J Biol Chem, 1989, 264, 2118–2125.
23 Weis JJ, Toothaker LE, Smith JA, Weis JH & Fearon DT. Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins [erratum published 168:1953–1954], J Exp Med, 1988, 167, 1047–1066.
24 Heyman B, Wiersma EJ & Kinoshita T. In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody, J Exp Med, 1991, 172, 665–668.[Medline]
25 Hebell T, Ahearn JM & Fearon DT. Suppression of the immune response by a soluble complement receptor of B lymphocytes, Science (Wash DC), 1991, 254, 102–105.
26 Ahearn JM, Fisher MB, Croix D, Goerg S, Ma MH, Xia JR, Zhou XN, Howard RG, Rothstein TJ & Carroll MC. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen, Immunity, 1996, 4, 251–262.[Medline]
27 Dempsey PW, Allison ME, Akkaraju S, Goodnow CC & Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity, Science (Wash DC), 1996, 271, 348–350.[Abstract]
28 Aubry JPS, Pochon S, Graber P, Jansen KU & Bonnefoy JY. CD21 is a ligand for CD23 and regulates IgE production, Nature (Lond), 1992, 385, 505–507.
29 Fearon DT & Carter RH. The CD19/CR2/ TAPA-1 complex of B lymphocytes: linking natural to acquired immunity, Annu Rev Immunol, 1995, 13, 127–149.[Medline]
30 Ahearn JM & Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21), Adv Immunol, 1989, 46, 183–219.[Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|